Genetic mutation blocks immune cell development, opening new drug target

Researchers identified how mutations in a single gene derail the formation of critical immune cells, offering a new pathway for treating a rare but severe immunodeficiency disorder. The finding could help pharmaceutical companies develop therapies for patients with activated PI3Kδ syndrome 2, a genetic condition that leaves people vulnerable to infections and cancer.

Originaltitel: Human <i>PIK3R1</i> mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2